Piper Sandler raised the firm’s price target on Bausch Health to $9 from $7 and keeps a Neutral rating on the shares. The firm is previewing the Q1 cycle for its coverage universe of SMid cap biopharma names, and with that in mind, a key consideration is the seasonality that is seen across the biopharma ecosystem.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BHC:
- Bausch Health price target lowered to $11 from $12 at RBC Capital
- Bausch Health put volume heavy and directionally bearish
- Jefferies healthcare analyst holds an analyst/industry conference call
- Bausch Health Wins Patent Appeal for XIFAXAN
- Bausch Health says ruling prevents FDA approval of Norwich ANDA until 2029
